1型长QT综合征的临床特征由C端Kv7.1变异引起的1型长QT综合征
Asami Kashiwa1, Hideki Itoh2, Takeru Makiyama3
1Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan; Department of Cardiology, Niigata City General Hospital, Niigata, Japan.
Heart rhythm
|February 17, 2024
概括
在KCNQ1基因中的变异位置影响长QT综合征 (LQTS) 的预后. 特定的C端变异,如p.R366W和p.T587M,与LQTS患者的心律失常结果的恶化有关.
科学领域:
- 遗传学 遗传学 是一个
- 心脏病学 心脏病学
- 分子生物学分子生物学
背景情况:
- 长QT综合征 (LQTS) 类型1是由编码KV7.1通道的KCNQ1基因的变异引起的.
- 在LQTS预后中Kv7.1 C末端区域的作用尚未完全理解.
- 了解基因型-表型相关性对于预测患者结果至关重要.
研究的目的:
- 研究Kv7.1 C末端变异的LQTS患者的临床特征和变异特异性风险.
- 阐明Kv7.1C末端变异的位置与心律失常风险之间的关系.
- 为了确定特定的变异及其相关的临床影响.
主要方法:
- 对202名连续LQTS患者 (98名试验者,104名家庭成员) 的分析,这些患者患有罕见的异合体Kv7.1C末端变异.
- 详细调查临床特征和心律失常事件.
- 对36种独特的C端变异的鉴定和定位分析.
主要成果:
- 确定了36种独特的C端变异,包括p.R366W和p.T587M,在日本西北部的众多家族中发现.
- 在高度保守和非螺旋域中的变异与更长的QTc间隔相关.
- 位于关键功能区域的p.R366W和p.T587M变异与其他C端变异相比,与更糟糕的心律失常结局有关.
结论:
- 在LQTS中,与Kv7.1 C末端变异相关的心律失常风险是异质的.
- 在LQTS中,Kv7.1 C末端变异的位置是预后的重要决定因素.
- 对特定变异位置的进一步研究可以完善LQTS患者的风险分层.
相关概念视频
Voltage-gated Ion Channels
8.2K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
8.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
996
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
996
Cardiac Action Potential
1.4K
Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832


